These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27989138)

  • 1. A History of the Molecular Initiating Event.
    Allen TE; Goodman JM; Gutsell S; Russell PJ
    Chem Res Toxicol; 2016 Dec; 29(12):2060-2070. PubMed ID: 27989138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
    Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
    ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining molecular initiating events in the adverse outcome pathway framework for risk assessment.
    Allen TE; Goodman JM; Gutsell S; Russell PJ
    Chem Res Toxicol; 2014 Dec; 27(12):2100-12. PubMed ID: 25354311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse outcome pathway (AOP) development I: strategies and principles.
    Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
    Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building a Network of Adverse Outcome Pathways (AOPs) Incorporating the Tau-Driven AOP Toward Memory Loss (AOP429).
    Tsamou M; Roggen EL
    J Alzheimers Dis Rep; 2022; 6(1):271-296. PubMed ID: 35891639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Putative adverse outcome pathways relevant to neurotoxicity.
    Bal-Price A; Crofton KM; Sachana M; Shafer TJ; Behl M; Forsby A; Hargreaves A; Landesmann B; Lein PJ; Louisse J; Monnet-Tschudi F; Paini A; Rolaki A; Schrattenholz A; Suñol C; van Thriel C; Whelan M; Fritsche E
    Crit Rev Toxicol; 2015 Jan; 45(1):83-91. PubMed ID: 25605028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adverse outcome pathway (AOP) for chemical binding to tubulin in oocytes leading to aneuploid offspring.
    Marchetti F; Massarotti A; Yauk CL; Pacchierotti F; Russo A
    Environ Mol Mutagen; 2016 Mar; 57(2):87-113. PubMed ID: 26581746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
    Kim M; Kim SH; Choi JY; Park YJ
    Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcome pathway from activation of the AhR to breast cancer-related death.
    Benoit L; Jornod F; Zgheib E; Tomkiewicz C; Koual M; Coustillet T; Barouki R; Audouze K; Vinken M; Coumoul X
    Environ Int; 2022 Jul; 165():107323. PubMed ID: 35660951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events.
    Proctor DM; Suh M; Chappell G; Borghoff SJ; Thompson CM; Wiench K; Finch L; Ellis-Hutchings R
    Regul Toxicol Pharmacol; 2018 Jul; 96():30-40. PubMed ID: 29684431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semantic characterization of adverse outcome pathways.
    Wang RL
    Aquat Toxicol; 2020 May; 222():105478. PubMed ID: 32278258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adverse outcome pathway concept: a pragmatic tool in toxicology.
    Vinken M
    Toxicology; 2013 Oct; 312():158-65. PubMed ID: 23978457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of an Adverse Outcome Pathway Network by Bayesian Regression and Bayesian Network Modeling.
    Moe SJ; Wolf R; Xie L; Landis WG; Kotamäki N; Tollefsen KE
    Integr Environ Assess Manag; 2021 Jan; 17(1):147-164. PubMed ID: 32965776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse outcome pathway-driven identification of rat liver tumorigens in short-term assays.
    Rooney J; Hill T; Qin C; Sistare FD; Corton JC
    Toxicol Appl Pharmacol; 2018 Oct; 356():99-113. PubMed ID: 30048669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development and application of adverse outcome pathway in toxicology research].
    Wang Y; Duan H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Dec; 49(12):1115-8. PubMed ID: 26887310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From papers to RDF-based integration of physicochemical data and adverse outcome pathways for nanomaterials.
    van Rijn JPM; Martens M; Ammar A; Cimpan MR; Fessard V; Hoet P; Jeliazkova N; Murugadoss S; Vinković Vrček I; Willighagen EL
    J Cheminform; 2024 May; 16(1):49. PubMed ID: 38693555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
    Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
    Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative systems biology strategy to support the development of adverse outcome pathways (AOPs): a case study on radiation-induced microcephaly.
    Jaylet T; Quintens R; Armant O; Audouze K
    Front Cell Dev Biol; 2023; 11():1197204. PubMed ID: 37427375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.